Previous Close | 1.5000 |
Open | 1.5000 |
Bid | 0.0000 x 40000 |
Ask | 0.0000 x 34100 |
Day's Range | 1.4800 - 1.6700 |
52 Week Range | 1.1100 - 5.9700 |
Volume | |
Avg. Volume | 4,041,343 |
Market Cap | 657.071M |
Beta (5Y Monthly) | 2.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0110 |
Earnings Date | Apr 27, 2022 - May 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.61 |
DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectiveness of VASCEPA® (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022, showcased significant potential to reduce major cardiovascular (CV) events and associated costs. The
DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.
DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, will present at two upcoming investor conferences: H.C. Wainwright Global Investment Conference (May 23-26, 2022; Miami, Florida) Date/Time: May 25, 2022, 12:00 p.m. ET/5:00 p.m. GMT+1Webcast: https://journey.ct.events/view/7aff40b1-3f90-47dd-a827-a30d854fea27 Jefferies Healthcare Conference (June 8-10, 20